Funds › Spruce Street Capital LP
Spruce Street Capital LP
13F for Q3 2026, filed Nov 13, 2026. 39 positions worth $629.0M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Spruce Street Capital LP in the latest 13F quarter?
Using 13F.ai, how has Spruce Street Capital LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Spruce Street Capital LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | KNSA Kiniksa Pharmaceuticals International, plc | 918,070 | $68.5M | 10.9% | Unchanged | 13F ↗ |
| 2 | RLAY Relay Therapeutics, Inc. | 2.98M | $53.9M | 8.6% | Unchanged | 13F ↗ |
| 3 | LBRX LB Pharmaceuticals Inc | 1.40M | $53.9M | 8.6% | +2.1% | 13F ↗ |
| 4 | ANRO Alto Neuroscience, Inc. | 1.68M | $42.8M | 6.8% | +23.9% | 13F ↗ |
| 5 | ALKS Alkermes plc | 948,471 | $38.4M | 6.1% | +74.4% | 13F ↗ |
| 6 | ENTX Entera Bio Ltd. | 11.21M | $32.6M | 5.2% | New | 13F ↗ |
| 7 | DNTH Dianthus Therapeutics, Inc. | 354,816 | $31.2M | 5.0% | Unchanged | 13F ↗ |
| 8 | SVRA Savara, Inc. | 5.38M | $27.8M | 4.4% | +55.9% | 13F ↗ |
| 9 | ZLAB Zai Lab Limited · ADR | 1.04M | $27.5M | 4.4% | +273% | 13F ↗ |
| 10 | RLMD Relmada Therapeutics, Inc. | 6.91M | $26.1M | 4.1% | +8.1% | 13F ↗ |
| 11 | PCVX Vaxcyte, Inc. | 306,047 | $17.4M | 2.8% | Unchanged | 13F ↗ |
| 12 | OBX Obsidian Therapeutics, Inc. | 1.25M | $17.2M | 2.7% | New | 13F ↗ |
| 13 | ELVN Enliven Therapeutics, Inc. | 329,006 | $15.1M | 2.4% | Unchanged | 13F ↗ |
| 14 | ENTA Enanta Pharmaceuticals, Inc. | 1.09M | $14.3M | 2.3% | Unchanged | 13F ↗ |
| 15 | SRZN Surrozen, Inc. | 432,040 | $13.9M | 2.2% | Unchanged | 13F ↗ |
| 16 | SGMT Sagimet Biosciences Inc. | 1.40M | $13.8M | 2.2% | New | 13F ↗ |
| 17 | YARW Yarrow Bioscience, Inc. | 607,382 | $13.7M | 2.2% | New | 13F ↗ |
| 18 | IFRX InflaRx N.V. | 6.09M | $11.0M | 1.7% | +13.7% | 13F ↗ |
| 19 | KRSA Korsana Biosciences, Inc. | 338,951 | $10.3M | 1.6% | New | 13F ↗ |
| 20 | CATX Perspective Therapeutics, Inc. | 3.69M | $10.2M | 1.6% | Unchanged | 13F ↗ |
| 21 | ANTX AN2 Therapeutics, Inc. | 1.75M | $9.3M | 1.5% | +5.5% | 13F ↗ |
| 22 | IKT Inhibikase Therapeutics, Inc. | 3.58M | $7.4M | 1.2% | Unchanged | 13F ↗ |
| 23 | SABS SAB Biotherapeutics, Inc. | 2.20M | $7.0M | 1.1% | Unchanged | 13F ↗ |
| 24 | IPSC Century Therapeutics, Inc. | 4.06M | $6.9M | 1.1% | Unchanged | 13F ↗ |
| 25 | ERAS Erasca, Inc. | 422,543 | $6.2M | 1.0% | Unchanged | 13F ↗ |
| 26 | ACHV Achieve Life Sciences, Inc. | 736,637 | $6.0M | 0.9% | Unchanged | 13F ↗ |
| 27 | NERV Minerva Neurosciences, Inc | 1.66M | $5.5M | 0.9% | Unchanged | 13F ↗ |
| 28 | RACC Research Alliance Corporation III | 500,000 | $5.4M | 0.9% | Unchanged | 13F ↗ |
| 29 | RACD Research Alliance Corporation IV | 450,000 | $5.4M | 0.9% | New | 13F ↗ |
| 30 | HLXC Helix Acquisition Corp. III | 500,000 | $5.3M | 0.8% | Unchanged | 13F ↗ |
| 31 | ATTO Attovia Therapeutics, Inc. | 228,295 | $3.9M | 0.6% | New | 13F ↗ |
| 32 | ALEC Alector, Inc. | 2.10M | $3.9M | 0.6% | Unchanged | 13F ↗ |
| 33 | TCGX TCGX Acquisition Corp. | 300,000 | $3.8M | 0.6% | New | 13F ↗ |
| 34 | LXEO Lexeo Therapeutics, Inc. | 928,593 | $3.1M | 0.5% | Unchanged | 13F ↗ |
| 35 | ALMS Alumis Inc. | 392,574 | $2.9M | 0.5% | Unchanged | 13F ↗ |
| 36 | CRVS Corvus Pharmaceuticals, Inc. | 231,585 | $2.7M | 0.4% | Unchanged | 13F ↗ |
| 37 | JATT JATT II Acquisition Corp | 160,000 | $1.8M | 0.3% | Unchanged | 13F ↗ |
| 38 | JTTT JATT III Acquisition Corp | 150,000 | $1.7M | 0.3% | New | 13F ↗ |
| 39 | LONA LeonaBio, Inc. | 393,701 | $1.4M | 0.2% | Unchanged | 13F ↗ |
Changes since Q2 2026
9 new, 8 added to, 0 trimmed, 0 exited, 22 unchanged. By estimated dollars.
New positions (9)
| ENTX Entera Bio Ltd. | 11.21M | New | $32.6M |
| OBX Obsidian Therapeutics, Inc. | 1.25M | New | $17.2M |
| SGMT Sagimet Biosciences Inc. | 1.40M | New | $13.8M |
| YARW Yarrow Bioscience, Inc. | 607,382 | New | $13.7M |
| KRSA Korsana Biosciences, Inc. | 338,951 | New | $10.3M |
| RACD Research Alliance Corporation IV | 450,000 | New | $5.4M |
| ATTO Attovia Therapeutics, Inc. | 228,295 | New | $3.9M |
| TCGX TCGX Acquisition Corp. | 300,000 | New | $3.8M |
| JTTT JATT III Acquisition Corp | 150,000 | New | $1.7M |
Added to (8)
| ZLAB Zai Lab Limited · ADR | 1.04M | +273% | $20.1M |
| ALKS Alkermes plc | 948,471 | +74.4% | $16.4M |
| SVRA Savara, Inc. | 5.38M | +55.9% | $10.0M |
| ANRO Alto Neuroscience, Inc. | 1.68M | +23.9% | $8.3M |
| RLMD Relmada Therapeutics, Inc. | 6.91M | +8.1% | $2.0M |
| IFRX InflaRx N.V. | 6.09M | +13.7% | $1.3M |
| LBRX LB Pharmaceuticals Inc | 1.40M | +2.1% | $1.1M |
| ANTX AN2 Therapeutics, Inc. | 1.75M | +5.5% | $483.8K |
Trimmed (0)
None this quarter.
Exited (0)
None this quarter.
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer